ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Why Do Clinical Trials Cost So Much? Looking Beyond The Obvious

  The true cost of research goes beyond budgets to design, data, and execution inefficiencies. Streamlining processes and early decisions reduces delays, controls costs, and improves study quality.

• CRF Validation Best Practices: Building Reliable Clinical Trial Databases

  CRF validation improves data quality and efficiency. Early planning, clear edit checks, and balance reduce rework, ease site burden, and enable more reliable, streamlined study execution.

• Why More Sponsors Are Taking Control Of Clinical Trial Study Builds

  Accelerate study startup and reduce rework by building studies directly in EDC. Discover a more flexible, efficient approach to managing clinical trials and data quality.

• RWD Into RWE: What Sponsors Need To Know For Trials

  Many sponsors are hesitant to incorporate RWD and RWE into their clinical trial ecosystems. In most cases, they are still determining where these data pools fit best into their workflows. But, if applied with precision, the data from real-world healthcare scenarios derisks the effort of bringing a molecule to market.

• Clinical Trial Participants Say It's One Of Their Biggest Burdens

  Travel to the study site shapes who enrolls, who stays compliant, and who completes a trial. Participant survey data shows where distance creates friction and which supports matter most.

• Why Travel Concierge Support Makes A Difference

  Where every participant is irreplaceable, sustained human support through relocation, crisis, and distance can decide whether a family completes a rare disease protocol. Three family stories illustrate the stakes.

• Improving Transparency And Credibility Of Real-World Evidence: The HARPER Template

  HARPER brings consistency to real-world evidence studies, improving transparency and reproducibility while supporting clearer evaluation of methods and findings.

• Beyond Healthcare Spending: The Evolving Definition Of Value In Health Policy

  As pharmaceutical policy takes on more goals, success is harder to define. Value extends beyond spending, requiring evidence that expected benefits are realized.

• Accelerating Enrollment For Direct-To-Patient Observational Studies

  Removing the handoff between patient self-screening and enrollment changes what a fully virtual observational study can achieve, from conversion at peak intent to completion rates among participants.

• Restoring The American Biotechnology Edge

  Michelle Longmire explores why startup delays, enrollment friction, fragmented systems, and rising costs put trials at a competitive disadvantage.